Stock AWKN AWAKN LIFE SCIENCES CORP.
Add to a list
To use this feature you must be a member
Log inSign up

All News Awakn Life Sciences Corp.

Equities

AWKN

CA05455W1086

Market Closed - Canadian Securities Exchange
Other stock markets
 19:42:10 07/05/2024 BST 		5-day change 1st Jan Change
0.195 CAD -7.14% Intraday chart for Awakn Life Sciences Corp. 0.00% +34.48%
04-03 Awakn Life Sciences Corp. Announces Launch of Licensing Partnership Agreement with Rivus Wellness and Research Institute CI
04-03 Awakn Life Sciences Corp. announced that it expects to receive CAD 1 million in funding CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CSE Bulletin: Suspensions - AWKN, BHCC, BZAM, GLOW, VTAL, JKPT, MEAL,VFI.X, STHZ
NE
Canadian Investment Regulatory Organization Trading Halt - AWKN
AQ
Awakn Life Sciences Discusses Filing of Financial Statements
NE
Awakn Life Sciences Announces Closing of Tranche of Private Placement
NE
Awakn Life Sciences Announces Launch of Licensing Partnership Agreement with Oklahoma Based Clinic
NE
Awakn Life Sciences Corp. Announces Launch of Licensing Partnership Agreement with Rivus Wellness and Research Institute
CI
Awakn Life Sciences Corp. announced that it expects to receive CAD 1 million in funding
CI
Canadian Securities Exchange Reports February 2024 Performance Figures
NE
CSE Bulletin: New Listing - Awakn Life Sciences Corp. (AWKN)
NE
Awakn Life Sciences Announces Listing on the Canadian Securities Exchange
NE
Awakn Life Sciences Announces Conditional Approval of CSE Listing
NE
Awakn Life Sciences Corp. Designates Program AWKN-002 for Alcohol Use Disorder in the US Market
CI
Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers
NE
Awakn Life Sciences Corp. Enters Global Licensing Agreement with LTS Lohmann Therapie-Systeme AG
CI
Awakn Life Sciences Enters Global Licensing Agreement For Proprietary Sublingual S-Ketamine Formulation With LTS
NE
Awakn Life Sciences Provides Corporate Update
NE
Awakn Life Sciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023
CI
Awakn Life Sciences Corp. Receives Clinical Trial Authorization from the Medicines and Healthcare Products Regulatory Agency and Health Research Authority in the UK for a Phase III Clinical Trial for its Lead Program AWKN-P001 for the Treatment of Severe Alcohol Use Disorder
CI
Awakn Life Sciences Receives Regulatory and Ethical Approval for Phase III Clinical Trial of AWKN-P001
NE
Awakn Life Sciences Announces Receipt of Notice of Non-Compliance with Cboe Exchange Continued Listing Requirements
NE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AWKN Stock
  4. News Awakn Life Sciences Corp.